biologics psoriasis: secukinumab
Selected indexed studies
- Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. (JAMA, 2020) [PMID:32427307]
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. (J Am Acad Dermatol, 2019) [PMID:30772098]
- Secukinumab in plaque psoriasis--results of two phase 3 trials. (N Engl J Med, 2014) [PMID:25007392]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. (2023) pubmed
- Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis. (2022) pubmed
- Secukinumab in plaque psoriasis--results of two phase 3 trials. (2014) pubmed
- Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. (2020) pubmed
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. (2019) pubmed
- Biologics for Psoriasis. (2024) pubmed
- Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation. (2024) pubmed
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials. (2023) pubmed
- Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence. (2024) pubmed
- Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis. (2024) pubmed